Cartesian Therapeutics, Inc.

Aug 6, 2026

Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Cartesian Therapeutics reported its Q2 2026 financial results, highlighting advancements in the Phase 3 AURORA trial for Descartes-08 in myasthenia gravis, with data expected in Q1 2027. The company also announced a partnership with WestGene to develop an in vivo CAR-T platform. Financially, Cartesian has secured up to $150 million in non-dilutive financing, ensuring operational support into 2028.

Cartesian Therapeutics Announces New Employment Inducement Grant

Cartesian Therapeutics has announced an employment inducement grant for a new employee, offering an option to purchase 6,100 shares at $5.86. This option, part of the company's incentive plan, vests over four years and has a ten-year term. The grant aims to attract talent as the company advances its clinical-stage cell therapies for autoimmune diseases.

Jun 9, 2026

▲ +16.9%on this news· ran to +62% by day 3shared move

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

Cartesian Therapeutics has entered a strategic licensing agreement with WestGene Biopharma to enhance the development of in vivo CAR-T therapies targeting autoimmune diseases. This collaboration aims to leverage WestGene's lipid nanoparticle platform and Cartesian's mRNA payload, with clinical trials expected to start in the second half of 2026. The partnership is anticipated to accelerate the path to clinical proof-of-concept data.

May 26, 2026

Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027

Cartesian Therapeutics has secured an agreement with K2 HealthVentures for up to $150 million in non-dilutive financing, with an initial $50 million tranche extending its cash runway into 2028. This funding will support multiple clinical programs, including the Phase 3 AURORA trial for Descartes-08 in myasthenia gravis, expected to yield topline data in the first quarter of 2027. The company is also advancing trials in myositis and juvenile dermatomyositis, reflecting ongoing commitment to its clinical pipeline. However, the announcement noted the planned departure of the CMO, which could affect company operations.

May 12, 2026

Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Cartesian Therapeutics, a late clinical-stage biotechnology company, will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The event will feature a fireside chat with management, which will be accessible via a live webcast. The company is focused on developing cell therapies for autoimmune diseases, with its lead asset currently in various phases of clinical development.

May 4, 2026

▲ +11.4%on this news· ran to +31% by day 3

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics, a biotechnology firm, has announced the issuance of employment inducement grants to five new hires. These grants include options to purchase 317,200 shares at a price of $6.22, aligning with the company's closing stock value on the grant date. The options will vest over a four-year period and were approved by the board of directors. This initiative aims to attract talent as the company advances its cell therapy programs for autoimmune diseases.

Apr 30, 2026

Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Cartesian Therapeutics reported its first quarter 2026 financial results, highlighting ongoing progress in multiple clinical trials for its lead candidate, Descartes-08. The company remains focused on its Phase 3 AURORA trial for myasthenia gravis, while also initiating a Phase 2 trial for myositis. Financially, Cartesian holds $120.4 million in cash, expected to support operations into mid-2027.

Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update

Cartesian Therapeutics reported its financial results for 2025, highlighting progress in the Phase 3 AURORA trial for Descartes-08 in myasthenia gravis. The company has sufficient cash reserves to support operations through mid-2027 and plans to initiate additional trials in myositis and juvenile dermatomyositis in 2026. CEO Carsten Brunn emphasized the potential of Descartes-08 to redefine treatment standards.

Feb 23, 2026

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

Cartesian Therapeutics, a clinical-stage biotechnology company, announced its participation in upcoming investor conferences in March and April 2026. The company is focused on cell therapy for autoimmune diseases and is advancing its lead asset, Descartes-08, into Phase 3 clinical trials for generalized myasthenia gravis. They also plan to initiate a Phase 2 trial for myositis.

Jan 9, 2026

Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook

Cartesian Therapeutics has made significant strides in its clinical pipeline, particularly with Descartes-08 for myasthenia gravis and myositis. The ongoing Phase 3 AURORA trial is progressing well, and the FDA has accepted the IND application for a pivotal trial in myositis. The company is also initiating a Phase 1/2 trial for juvenile dermatomyositis, showcasing its commitment to advancing treatments for autoimmune diseases.

Dec 18, 2025

Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors

Cartesian Therapeutics has appointed Dr. Adrian Bot to its Board of Directors, bringing over 30 years of experience in biopharma, particularly in cell therapy and immune engineering. Dr. Bot, known for his work in CAR T cell therapies, will contribute to the Science and Technology Committee as the company focuses on advancing its clinical pipeline. Cartesian is currently developing its lead asset, Descartes-08, which is in Phase 3 trials for generalized myasthenia gravis and has plans for trials in myositis.

Nov 13, 2025

Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis

Cartesian Therapeutics announced positive results from its Phase 2 trial of Descartes-08 in patients with systemic lupus erythematosus (SLE), achieving a 100% response rate at Month 3. The therapy demonstrated a favorable safety profile, allowing for outpatient administration. The company plans to expand clinical development into myositis, with a pivotal trial expected to start in the first half of 2026.

Nov 6, 2025

Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Cartesian Therapeutics reported its third quarter 2025 financial results, highlighting progress in its clinical trials. The Phase 3 AURORA trial for Descartes-08 in myasthenia gravis is on track, with preliminary data from a Phase 2 trial in systemic lupus erythematosus expected by year-end. The company has a solid financial foundation to support ongoing operations into mid-2027.

Oct 30, 2025

Cartesian Therapeutics Announces Carsten Brunn, Ph.D., Named as Chairman of the Company’s Board of Directors

Cartesian Therapeutics has appointed Carsten Brunn, Ph.D., as the new Chairman of the Board, effective October 29, 2025. Brunn, who is also the President and CEO, succeeds Carrie S. Cox, who is stepping down for other commitments. The company is focused on advancing its lead asset, Descartes-08, towards regulatory submission and commercial launch.

Cartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Initiated Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Preliminary data from Phase 2 trial of Descartes-08 in

Cartesian Therapeutics has announced its financial results for Q2 2025, highlighting the initiation of the Phase 3 AURORA trial for Descartes-08, a CAR-T therapy targeting myasthenia gravis. The company reported $162.1 million in cash to support operations until mid-2027, allowing continued focus on clinical development. Preliminary data from a Phase 2 trial for systemic lupus erythematosus is anticipated later this year. However, R&D expenses have risen, leading to a slight decrease in net income compared to the previous year.

May 30, 2025

Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis

Cartesian Therapeutics has enrolled the first participant in its Phase 3 AURORA trial for Descartes-08, a CAR-T therapy for myasthenia gravis. This trial aims to evaluate the therapy against placebo in approximately 100 participants. Descartes-08 has shown promising results in earlier trials, with sustained benefits observed over 12 months.

May 13, 2025

Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

Cartesian Therapeutics, a clinical-stage biotechnology firm, will participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025. The event will feature a fireside chat with management, highlighting the company's innovative cell therapy for autoimmune diseases. Cartesian's lead asset, Descartes-08, is advancing through clinical trials for conditions like generalized myasthenia gravis and systemic lupus erythematosus.

May 8, 2025

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Initiation of Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 2Q25 deep and sustained benefits observ

Cartesian Therapeutics reported its first quarter financial results for 2025 alongside updates on its clinical pipeline. The company expects to initiate the Phase 3 AURORA trial of Descartes-08 for myasthenia gravis in the second quarter of 2025, following promising interim results from a Phase 2b trial showing sustained benefits over 12 months. Additionally, Cartesian plans to provide preliminary data for Descartes-08 in systemic lupus erythematosus later in 2025 and initiate a pediatric trial. The company's financial health appears robust, with significant cash reserves to support their developments through mid-2027.

Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial After a single course of therapy, Descartes-08-tr

Cartesian Therapeutics reported promising 12-month results from its Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis. Participants experienced significant and sustained improvements in symptoms, particularly among those without prior biologic therapy, achieving an average reduction of 7.1 points on the MG-ADL scale. The treatment demonstrated a favorable safety profile that supports its outpatient administration, with no new adverse events reported. The company is preparing to initiate a Phase 3 AURORA trial in the second quarter of 2025 to further evaluate Descartes-08's efficacy and safety.

Apr 1, 2025

▼ -5.2%on this news· ran to -24% by day 3shared move

Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Cartesian Therapeutics, a clinical-stage biotechnology company, announced its management's participation in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on April 8, 2025. The event will feature a live webcast accessible on the company's website. Cartesian is recognized for its pioneering mRNA cell therapies targeting autoimmune diseases, with its lead asset Descartes-08 currently advancing in clinical trials for generalized myasthenia gravis and systemic lupus erythematosus. Additionally, the company is developing Descartes-15 for multiple myeloma.

Mar 13, 2025

Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25 Deep and durable responses maintained ov

Cartesian Therapeutics has announced its financial results for 2024 and provided an update on its business, including plans to commence the Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) in the first half of 2025. The company reported strong financials with $214.3 million in cash expected to support its pipeline and operations into mid-2027. Moreover, positive results were noted from the Phase 2b trial, highlighting durable responses to the treatment, while ongoing trials in systemic lupus erythematosus and pediatric basket indications are anticipated to yield further data by the end of 2025.

Jan 27, 2025

Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis

Cartesian Therapeutics has announced that it received FDA Special Protocol Assessment for its Phase 3 AURORA trial of Descartes-08, an mRNA cell therapy for myasthenia gravis. This agreement confirms that the trial design is acceptable for supporting a potential Biologics License Application. The positive results from the prior Phase 2b trial showed significant improvements in patient scores. The upcoming Phase 3 trial aims to further validate the effectiveness of Descartes-08 without preconditioning chemotherapy.

Cartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of mRNA Cell Therapies for Autoimmune Diseases

Cartesian Therapeutics announced significant progress in its pipeline of mRNA cell therapies targeting autoimmune diseases. The company is set to commence its Phase 3 AURORA trial for Descartes-08 in patients with myasthenia gravis in the first half of 2025, having reported positive Phase 2b results indicating deepening responses. Additionally, Cartesian is pursuing trials for systemic lupus erythematosus and pediatric autoimmune conditions, while it continues the development of its next-generation CAR-T therapy, Descartes-15. Overall, the company is positioned favorably for continued advancements in its research and trials throughout 2025.

Dec 3, 2024

Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial

Cartesian Therapeutics has announced positive updated results from the Phase 2b trial of Descartes-08 for myasthenia gravis, showing significant improvements in MG-ADL scores. The therapy demonstrated safety and a durable response in participants over 12 months. A Phase 3 trial, AURORA, is planned to begin in the first half of 2025, aiming to further assess Descartes-08's efficacy and safety. The results have been shared at a key conference, highlighting the potential of Descartes-08 as a treatment for this rare autoimmune disorder.

Nov 21, 2024

Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit

Cartesian Therapeutics, Inc. has announced it will present updated data from its Phase 2b trial of Descartes-08 at the upcoming 2nd Annual Cell Therapy for Autoimmune Disease Summit in December 2024. The presentation will include insights on the challenges and successes in developing cell therapies for autoimmune diseases. Descartes-08 is currently being studied for its efficacy and safety in patients with generalized myasthenia gravis and holds several designations from the FDA, highlighting its promise in treatment options for this condition and others.

Nov 7, 2024

Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Company expects to commence Phase 3 trial of Descartes-08 in patients with myasthenia gravis in 1H2025 following recent mee

Cartesian Therapeutics has reported its financial results for Q3 2024 and provided updates on its clinical pipeline. The company expects to commence a Phase 3 trial of its lead candidate, Descartes-08, for treating myasthenia gravis in the first half of 2025, following positive data from the Phase 2b trial. Additionally, the company is actively pursuing studies for systemic lupus erythematosus and juvenile dermatomyositis. Cartesian is well-funded with approximately $220.9 million to support its clinical programs into mid-2027.

Nov 5, 2024

Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting

Cartesian Therapeutics has announced that it will present safety and tolerability data from its lead mRNA cell therapy candidate, Descartes-08, at the upcoming 66th ASH Annual Meeting. This innovative therapy targets B-cell maturation antigen and is in clinical development for autoimmune diseases such as generalized myasthenia gravis and systemic lupus erythematosus. The poster presentation, scheduled for December 7, 2024, has been selected for a special Poster Walk session, showcasing advancements in blood immunology and cellular therapy. Cartesian's focus on mRNA CAR-T therapy aims to improve treatment delivery and reduce risks associated with conventional methods.

Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting

Cartesian Therapeutics has announced the presentation of data from its Phase 2b trial of Descartes-08, an mRNA CAR-T therapy for generalized myasthenia gravis, at the 2024 MGFA Scientific Session. The trial showed positive topline results with 71% of patients experiencing significant improvement in MG Composite score. Descartes-08 also demonstrated a favorable safety profile, allowing treatment in an outpatient setting without preconditioning chemotherapy. The company plans to collaborate with the FDA for the next phase in its development.

Sep 9, 2024

Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis

Cartesian Therapeutics has received Rare Pediatric Disease Designation from the FDA for its mRNA cell therapy candidate, Descartes-08, intended for the treatment of juvenile dermatomyositis. This designation recognizes the potential of Descartes-08 to address unmet medical needs in an underserved pediatric population. The therapy does not require preconditioning chemotherapy, which may facilitate its administration. The company is on track to file an Investigational New Drug application by the end of the year for a Phase 2 pediatric basket study including JDM and other autoimmune conditions.

Sep 3, 2024

▼ -6%on this newsshared move

Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15

Cartesian Therapeutics has initiated its Phase 1 trial for Descartes-15, a novel mRNA CAR-T cell therapy aimed at treating autoimmune diseases. The therapy has showed promising preclinical results, achieving a significant increase in CAR expression and the potential for outpatient administration without prior chemotherapy. The trial will focus on multiple myeloma patients and may expand to additional autoimmune conditions following this initial phase. The advancement of this therapy is seen as a significant step in the company's objective to innovate treatment options for conditions with high unmet medical needs.

Cartesian Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Presented positive topline results from Phase 2b trial of Descartes-08 in patients with myasthenia gravis End-of-Phase 2 m

Cartesian Therapeutics reported its second quarter financial results, highlighting positive topline outcomes from the Phase 2b trial of Descartes-08 for myasthenia gravis, achieving statistical significance. The company has also dosed its first patient in a Phase 2 trial for systemic lupus erythematosus and plans to file an IND for pediatric autoimmune diseases by year-end. Furthermore, a recent PIPE financing raised approximately $130 million to facilitate the ongoing development of Descartes-08, with an anticipated Phase 3 trial on the horizon. The company expects to have discussions with the FDA regarding future plans and clinical trials.

Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik

Cartesian Therapeutics has appointed Dr. Kemal Malik to its Board of Directors, bringing over 30 years of pharmaceutical expertise. Dr. Malik's notable experience includes leading global development at Bayer, where he oversaw numerous successful clinical trials and drug approvals. His addition is expected to be instrumental as Cartesian progresses its pipeline of mRNA cell therapies aimed at autoimmune diseases, including potential first-in-class candidates. The company's focus is on delivering innovative therapies to patients with limited options.

Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus

Cartesian Therapeutics has announced the first patient dosing in its Phase 2 trial for Descartes-08, an mRNA cell therapy for systemic lupus erythematosus (SLE). This therapy is designed to target the B-cell maturation antigen and aims to provide an outpatient treatment option without the risks associated with traditional DNA-based CAR-T therapies. The trial is expected to enroll 30 adult patients and will evaluate safety and tolerability. Descartes-08's development stems from a previous trial for myasthenia gravis, showing a favorable safety profile.

Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis

Cartesian Therapeutics announced positive topline results from its Phase 2b trial of Descartes-08 in patients with myasthenia gravis, demonstrating statistically significant improvement in patient MGC scores. The trial showed that 71% of patients treated with Descartes-08 experienced clinically meaningful improvements compared to 25% for placebo. In addition, the treatment maintained a favorable safety profile, supporting outpatient administration without the need for lymphodepleting chemotherapy. The company is set to hold an End-of-Phase 2 meeting with the FDA by year-end to discuss the next steps for the therapy.

Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing GAITHERSBURG, MD

Cartesian Therapeutics has announced a private placement equity financing expected to generate approximately $130 million in gross proceeds. This financing involves the sale of common stock and non-voting convertible preferred stock to both new and existing investors, with closing anticipated around July 3, 2024. The funds will primarily support the company's pipeline programs and general corporate purposes. Notably, the company is developing mRNA therapies aimed at treating autoimmune diseases, including generalized myasthenia gravis and systemic lupus erythematosus.

May 22, 2024

Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis

Cartesian Therapeutics has been granted Regenerative Medicine Advanced Therapy designation by the FDA for its lead product, Descartes-08, an mRNA CAR-T therapy aimed at treating myasthenia gravis. This designation acknowledges its potential to address unmet medical needs in this area. The company plans to report topline data from its Phase 2b study later this year, following successful early results from a Phase 2a study. The therapy has previously received Orphan Drug Designation for myasthenia gravis, demonstrating its promise in the treatment landscape for this chronic autoimmune disorder.

May 13, 2024

Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Cartesian Therapeutics, Inc. will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference on May 20, 2024. The event will feature a fireside chat with company management, and a live webcast will be available on the company's website. Cartesian Therapeutics is focused on developing mRNA cell therapies, with its lead candidate, Descartes-08, currently in Phase 2b clinical development for myasthenia gravis. The company is also advancing additional studies in systemic lupus erythematosus and other autoimmune conditions.

May 8, 2024

Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Topline data from Phase 2b trial of Descartes-08, the Company's potential first-in-class mRNA CAR-T cell therapy, in myasth

Cartesian Therapeutics reported its financial results for the first quarter of 2024, showcasing a robust cash position with approximately $104.8 million available. The company is on track to provide topline data from its Phase 2b trial for Descartes-08, an mRNA CAR-T therapy for myasthenia gravis, by mid-2024. Additionally, plans for a Phase 2 trial of Descartes-08 in systemic lupus erythematosus are set to commence in the second quarter of 2024. However, the company reported a significant net loss and increased expenses related to professional fees from a recent merger.

Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split Proposals approved at Company's special meeting of stockholders held

Cartesian Therapeutics announced the approval of conversion for its Series A Convertible Preferred Stock and a 1-for-30 reverse stock split, set to take effect on April 4, 2024. This decision was made during a special shareholder meeting held on March 27, 2024, where stockholders showed their support for both proposals. Following the split, the total shares outstanding will significantly decrease, impacting the company's stock trading from April 5, 2024. The company is also advancing its clinical-stage pipeline for autoimmune diseases.

Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update Topline data from Phase 2b study of Descartes-08, the Company's potential first-in-class mRNA CAR-T cell therapy, in myasthenia

Cartesian Therapeutics has reported its financial results for the year ending December 31, 2023, along with significant business updates. The company anticipates topline data from the Phase 2b study of its lead candidate, Descartes-08, in myasthenia gravis to be released in mid-2024. Additionally, Cartesian is preparing to initiate Phase 2 trials for systemic lupus erythematosus and has received IND clearance to begin first-in-human studies for Descartes-15. The company plans to hold a special stockholder meeting to approve a preferred stock conversion and a reverse stock split.

Mar 5, 2024

Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland - New facility expected to support expanded cGMP manufacturing of cl

Cartesian Therapeutics has announced the relocation of its corporate headquarters to Frederick, Maryland, along with the establishment of a new state-of-the-art cGMP manufacturing facility. The facility, spanning approximately 20,000 square feet, aims to enhance the production of the company's mRNA cell therapies for autoimmune diseases. This move is intended to bolster their manufacturing capabilities for late-stage clinical and commercial supply. Additionally, Cartesian's lead product, Descartes-08, is in Phase 2b clinical development, with data expected in mid-2024.

Jan 8, 2024

▲ +5.9%on this news· ran to +36% by day 3

THERAPEUTICS Pioneering mRNA Cell Therapy for Autoimmunity January 2024 C A R T ES I AN T H E R APEUT I CS Forward-Looking Statements Disclosures For the purposes of this notice, the "presentation" that follows shall mea

Cartesian Therapeutics is advancing mRNA cell therapies targeting autoimmune diseases, emphasizing outpatient administration without lymphodepletion. The company reports promising Phase 2a study results with Descartes-08 for myasthenia gravis, showcasing potential for safe re-dosing and scalability. Upcoming milestones include Phase 2b data and initiation of studies for systemic lupus erythematosus and other indications, supported by recent financing. However, the company faces various uncertainties and risks inherent in clinical development and regulatory processes.

Jan 8, 2024

▲ +5.9%on this news· ran to +36% by day 3

Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity

Cartesian Therapeutics provided an update on its mRNA cell therapy pipeline following a transformative year in 2023. The company is on track to release topline data for its lead asset, Descartes-08, in mid-2024, after observing positive results from a Phase 2a trial in myasthenia gravis (MG). Additionally, IND clearance for Descartes-15, a next-generation CAR-T therapy, has been announced, with plans for future studies in systemic lupus erythematosus (SLE) and other autoimmune conditions. Cartesian's robust cash reserves are expected to sustain its research and development activities through 2026.

Jan 8, 2024

▲ +5.9%on this news· ran to +36% by day 3

Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis

Cartesian Therapeutics announced positive long-term follow-up data from its Phase 2a trial of Descartes-08, an mRNA cell therapy for generalized myasthenia gravis (MG). Patients showed durable clinical improvements and reductions in autoantibody levels after one year, without requiring lymphodepleting chemotherapy. The data build upon earlier findings of the therapy's safety and efficacy. Additionally, a Phase 2b placebo-controlled study is underway to further investigate Descartes-08's potential, with topline results anticipated in mid-2024.

Nov 13, 2023

Disclosures For the purposes of this notice, the "presentation" that follows shall mean and include the slides that follow, the oral presentation of the slides by members of management of Selecta Biosciences, Inc. ("Sele

Selecta Biosciences, Inc. is in the process of a proposed merger with Cartesian Therapeutics, Inc., which will involve a wholly-owned subsidiary of Selecta. This presentation is intended to facilitate discussions and evaluations by qualified institutional buyers and accredited investors regarding the merger and related financial transactions. Important details surrounding the merger process, potential benefits, and associated risks have been outlined for stakeholders. Furthermore, the presentation clarifies that it does not serve as investment advice and encourages independent evaluation.

Aug 17, 2023

Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics Company to continue focusing on advancement o

Selecta Biosciences has reported its financial results for the second quarter of 2023 and provided updates regarding its strategic initiatives aimed at maximizing stockholder value, particularly concerning its treatment for chronic refractory gout, SEL-212. The company plans to focus resources on advancing SEL-212 and will stop investing in most of its pipeline assets to preserve capital. Selecta holds a cash position expected to sustain operations through 2027 but reported a net loss in this quarter, differing from the prior year's gain.

Mar 21, 2023

Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint Response rate of 56% in patients treated monthly with high dose SEL-212 in DISSOLVE I and 47% in DISSOLVE II In patients 50 years and

Selecta Biosciences and Sobi announced positive topline results from the Phase 3 DISSOLVE I and II trials for SEL-212 in patients with chronic refractory gout. The trials demonstrated a 56% response rate in DISSOLVE I and 47% in DISSOLVE II, suggesting significant efficacy for the treatment. The product exhibited favorable safety with a low rate of infusion reactions. SEL-212 combines Selecta's ImmTOR platform with pegadricase, representing a promising new option for patients suffering from this debilitating condition.

Jan 9, 2023

Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease Next-generation IgG protease candidate Xork to be licensed for development with AT845, an invest

Selecta Biosciences and Astellas Pharma have entered into an exclusive licensing and development agreement for Xork, a next-generation IgG protease. This collaboration aims to use Xork with AT845, a gene therapy for Late-Onset Pompe Disease. Selecta will receive an upfront payment of $10M, with additional potential milestones totaling up to $340M, in addition to royalties on future sales. The agreement is designed to improve treatment access for patients who may not qualify for existing gene therapy trials due to pre-existing antibodies.

Dec 14, 2022

Selecta Biosciences Announces Next Generation IgA Protease Clinical Candidate Selection for IgA Nephropathy Program - IgA protease candidate in combination with ImmTOR further enhances pipeline - - Novel mechanism of act

Selecta Biosciences Announces Next Generation IgA Protease Clinical Candidate Selection for IgA Nephropathy Program -IgA protease candidate in combination with ImmTOR further enhances pipeline - - Novel mechanism of action of IgA protease has the potential to address the under

Nov 28, 2022

Selecta Biosciences Announces Appointment of Blaine Davis as Chief Financial Officer

Selecta Biosciences Announces Appointment of Blaine Davis as Chief Financial Officer WATERTOWN, Mass. November 28, 2022 Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies for auto

Nov 3, 2022

Selecta Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update - DISSOLVE I II studies of SEL-212 in Chronic Refractory Gout remain on track for joint topline data readout in Q1 2023 - - SE

Selecta Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update - DISSOLVE I II studies of SEL-212 in Chronic Refractory Gout remain on track for joint topline data readout in Q1 2023 - - SEL-302, Selecta's wholly owned gene therapy in combination

Aug 4, 2022

Selecta Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update - Completed enrollment of DISSOLVE II, triggering a $10 million milestone payment obligation from Swedish Orphan Biovitrum AB

Selecta Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update - Completed enrollment of DISSOLVE II, triggering a $10 million milestone payment obligation from Swedish Orphan Biovitrum AB (publ.) (Sobi) DISSOLVE I II studies remain on track for

Jun 13, 2022

Selecta Biosciences Announces Partnership Advancements and Clinical Trial Updates Sarepta extends Research License and Option Agreement for ImmTOR in Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophi

Selecta Biosciences Announces Partnership Advancements and Clinical Trial Updates Sarepta extends Research License and Option Agreement for ImmTOR in Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophies- Selecta to receive a $2 million payment from Sarepta

May 18, 2022

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE ANTHONY FRANCHI, derivatively on behalf of Nominal Defendant SELECTA BIOSCIENCES, INC., Plaintiff, v. TIMOTHY C. BARABE, CARSTEN BRUNN, CARRIE S. COX, SCOTT D. MYERS, AMI

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE NOTICE OF PENDENCY OF SETTLEMENT OF DERIVATIVE ACTION TO ALL CURRENT STOCKHOLDERS OF SELECTA BIOSCIENCES, INC. (TRADING SYMBOL SELB) PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. YOUR RIGHTS WILL BE AFFECTED BY THE LEG

May 5, 2022

Selecta Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update Phase 1 trial of SEL-302 remains on track to initiate in the second half of 2022 DISSOLVE I II studies on track for completion

Selecta Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update Phase 1 trial of SEL-302 remains on track to initiate in the second half of 2022 DISSOLVE I II studies on track for completion in Q4 2022 with joint topline readout in Q1 2023 Comple

Apr 6, 2022

Selecta Biosciences Announces $38.7 Million Underwritten Offering

Selecta Biosciences Announces $38.7 Million Underwritten Offering WATERTOWN, Mass., April 6, 2022 Selecta Biosciences, Inc. (Nasdaq: SELB) ( Selecta or the Company ), a biotechnology company focused on developing tolerogenic therapies to mitigate unwanted immune responses, toda

Apr 6, 2022

SELB April 2022 Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. (the "Company"), including without limitation, statements regarding the Company's cash r

Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. (the "Company"), including without limitation, statements regarding the Company's cash runway, the unique proprietary technology platform of the Company, and the u

Mar 10, 2022

Selecta Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update U.S. Food and Drug Administration ("FDA") removed clinical hold on SEL-302 for the treatment of patients with m

Selecta Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update U.S. Food and Drug Administration ("FDA") removed clinical hold on SEL-302 for the treatment of patients with methylmalonic acidemia ("MMA") Observed the synergy of Imm

Nov 24, 2021

Selecta Biosciences Provides Update on Phase 1/2 Clinical Trial of SEL-302 for the Treatment of Methylmalonic Acidemia -U.S. FDA has issued a clinical hold on Phase 1/2 Clinical Trial of SEL-302 due to CMC related questi

Selecta Biosciences Provides Update on Phase 1/2 Clinical Trial of SEL-302 for the Treatment of Methylmalonic Acidemia -U.S. FDA has issued a clinical hold on Phase 1/2 Clinical Trial of SEL-302 due to CMC related questions- WATERTOWN, MA, November 24, 2021 Selecta Bioscience

Nov 9, 2021

Selecta Biosciences Reports Third Quarter 2021 Financial Results and Provides Business Update Established four strategic collaborations to advance next generation therapeutics and maximize the potential of ImmTOR platfor

Selecta Biosciences Reports Third Quarter 2021 Financial Results and Provides Business Update Established four strategic collaborations to advance next generation therapeutics and maximize the potential of ImmTOR platform Reported topline data from SEL-399 (empty AAV8 capsid in

Nov 8, 2021

SELB AAV8 Empty Capsid plus ImmTOR (SEL-399) Human Proof-Of-Concept Study* T op Line Data Report of a Phase 1 Clinical Study in Healthy Volunteers

Proof-Of-Concept Study* T op Line Data Report of a Phase 1 Clinical Study in Healthy Volunteers November 8, 2021 * Joint study with AskBio Safe Harbor / Disclaimer Any statem ents in this presentation about the future expectations, plans and prospects of Selecta Biosciences, In

Aug 12, 2021

Selecta Biosciences Reports Second Quarter 2021 Financial Results and Provides Business Update IND filing for wholly owned gene therapy program, SEL-302 (MMA-101, in combination with ImmTOR) in methylmalonic acidemia (MM

Selecta Biosciences Reports Second Quarter 2021 Financial Results and Provides Business Update IND filing for wholly owned gene therapy program, SEL-302 (MMA-101, in combination with ImmTOR) in methylmalonic acidemia (MMA) expected during the third quarter of 2021 Manufacturing

May 13, 2021

Selecta Biosciences Reports First Quarter 2021 Financial Results and Provides Business Update SEL-399 (empty AAV8 capsid with ImmTOR) study on track with topline data expected in the fourth quarter of 2021 SEL-212 enroll

Selecta Biosciences Reports First Quarter 2021 Financial Results and Provides Business Update SEL-399 (empty AAV8 capsid with ImmTOR) study on track with topline data expected in the fourth quarter of 2021 SEL-212 enrollment on track with topline data from DISSOLVE phase 3 prog

Apr 29, 2021

Selecta Biosciences and AskBio Announce Updates to Methylmalonic Acidemia (MMA-101) Program Methylmalonic Acidemia ( MMA) program to become wholly-owned by Selecta Selecta to postpone IND submission until at least the fo

Selecta Biosciences and AskBio Announce Updates to Methylmalonic Acidemia Methylmalonic Acidemia (MMA) program to become wholly-owned Selecta to postpone IND submission until at least the fourth quarter of 2021 Empty capsid (SEL-399) study remains on track WATERTOWN, Mass., a

Mar 11, 2021

Selecta Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results First-in-human dose-escalation study to evaluate ability of ImmTOR to mitigate immunogenicity of AAV capsid i

Selecta Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results First-in-human dose-escalation study to evaluate ability of ImmTOR to mitigate immunogenicity of AAV capsid initiated with initial data expected in the fourth quarter o

Jan 6, 2021

Selecta Biosciences Announces Data in Non-Human Primates, Further Validating Multiple Potential Benefits of the ImmTOR TM Platform in Gene Therapy Co-administration of AAV8 and ImmTOR shows first dose benefit of higher a

Selecta Biosciences Announces Data in Non-Human Primates, Further Validating Multiple Potential Benefits of the ImmTORTM Platform in Gene Therapy Co-administration of AAV8 and ImmTOR shows first dose benefit of higher and more durable transgene expression, in addition to mitigat

Nov 5, 2020

Selecta Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Updates Phase 3 DISSOLVE clinical program with Sobi ongoing to evaluate SEL-212 topline data expected in the second half of 2022 IND

Selecta Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Updates Phase 3 DISSOLVE clinical program with Sobi ongoing to evaluate SEL-212 topline data expected in the second half of 2022 IND filing for gene therapy expected in Q1 2021 preliminary P

Sep 30, 2020

Phase 2 COMPARE Trial Topline Data Presentation

Phase 2 COMPARE Trial Topline Data Presentation September 30, 2020 Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. ("the com pan y"), including without limitation, statements regarding the clinical development,

Aug 6, 2020

Selecta Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Updates Closed strategic licensing agreement with Sobi for SEL-212 for $100 million in initial payments and up to $630 million in p

Selecta Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Updates Watertown, Mass., August 6, 2020 - Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies base

May 7, 2020

Selecta Biosciences Reports First Quarter 2020 Financial Results Topline data announcement from the ongoing head-to-head COMPARE trial of SEL-212 remains on schedule for Q3 2020 Phase 3 clinical program of SEL-212 to com

Selecta Biosciences Reports First Quarter 2020 Financial Results Watertown, Mass., May 7, 2020 - Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform,

Mar 12, 2020

Selecta Biosciences Reports Fourth Quarter 2019 and Year-End Financial Results Topline results from head-to-head COMPARE trial of SEL-212 in chronic refractory gout expected in Q3 2020 Received guidance from the FDA on S

Selecta Biosciences Reports Fourth Quarter 2019 and Year-End Financial Results Watertown, Mass., Mar. 12, 2020 - Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tol

Nov 8, 2019

Selecta Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update Compelling preclinical data presented at the European Society of Gene and Cell Therapy Annual Congress demonstrates the poten

Selecta Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update Watertown, Mass., Nov. 8, 2019 - Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on

Aug 8, 2019

Selecta Biosciences Reports Second Quarter 2019 Financial Results and Provides Corporate Update New strategic partnership with gene therapy leader, AskBio, to jointly develop next-generation AAV-based gene therapies to a

Selecta Biosciences Reports Second Quarter 2019 Financial Results and Provides Corporate Update Watertown, Mass., August 8, 2019 - Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based

Aug 7, 2019

Selecta Biosciences Combines ImmTOR Platform with AskBio's Industry-Leading Gene Therapy Platform in Strategic Partnership Development pipeline and human trials planned for repeat dosing of AAV-based gene therapies to ad

Selecta Biosciences Combines ImmTOR Platform with AskBio's Industry-Leading Gene Therapy Platform in Strategic Partnership Development pipeline and human trials planned for repeat dosing of AAV-based gene therapies to address the unmet medical need for patients with rare and orp

May 9, 2019

Selecta Biosciences Reports First Quarter 2019 Financial Results and Provides Corporate Update Patient enrollment ongoing in COMPARE trial evaluating efficacy and safety of SEL-212 vs. KRYSTEXXA in patients with chronic

Selecta Biosciences Reports First Quarter 2019 Financial Results and Provides Corporate Update Watertown, Mass., May 9, 2019 - Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on

Mar 15, 2019

Selecta Biosciences Announces Fourth Quarter and Year End 2018 Financial Results and Provides Corporate Update Phase 2 head-to-head (COMPARE) clinical trial of SEL-212 vs. KRYSTEXXA to begin in 1Q19, interim six-month da

Selecta Biosciences Announces Fourth Quarter and Year End 2018 Financial Results and Provides Corporate Update Watertown, Mass., March 15, 2019 - Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic

Jan 7, 2019

january2019jpm Company Presentation January 2019 SELB 1 Safe Harbor / Disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. ("the company"), includ

Company Presentation January 2019 SELB 1 Safe Harbor / Disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. ("the company"), including without limitation, statements regarding the progress of the clinical

Jan 3, 2019

Selecta Biosciences Expands Potential for ImmTOR Platform and Streamlined Structure Under Leadership of New CEO, Carsten Brunn, Ph.D.

Selecta Biosciences Expands Potential for ImmTOR Platform and Streamlined Structure Under Leadership of New CEO, Carsten Brunn, Ph.D. Watertown, Mass., January 3, 2019 - Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biotechnology company focused on unlocking the ful

Nov 8, 2018

Selecta Biosciences Announces Third Quarter 2018 Financial Results and Provides Corporate Update Prioritized head-to-head superiority clinical trial of SEL-212 compared to Krystexxa, expected to begin in the first quarte

Selecta Biosciences Announces Third Quarter 2018 Financial Results and Provides Corporate Update Watertown, Mass., Nov. 8, 2018 - Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies b

Oct 23, 2018

Selecta Biosciences Presents New Interim Data from Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at ACR 2018 Interim analysis indicates serum uric acid (SUA) control has been maintained into months fo

Selecta Biosciences Presents New Interim Data from Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at ACR 2018 Watertown, Mass., October 23, 2018 - Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the ful

Aug 8, 2018

Selecta Biosciences Announces Second Quarter 2018 Financial Results and Provides Corporate Update Expanded three-month Phase 2 data presented at EULAR 2018 continue to indicate that SEL-212 product profile may provide be

Selecta Biosciences Announces Second Quarter 2018 Financial Results and Provides Corporate Update Watertown, Mass., Aug. 8, 2018 - Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies

Jun 15, 2018

Selecta Biosciences Presents Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at EULAR 2018 3-month Phase 2 data continue to show SEL-212 (SVP-Rapamycin + pegsiticase) may present a sup

Selecta Biosciences Presents Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at EULAR 2018 Watertown, Mass., June 15, 2018 - Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full pot

Jun 4, 2018

jefferiesinvestorpr Jefferies Presentation Nasdaq: SELB June 2018 Safe Harbor / Disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. ("the company

Jefferies Presentation Nasdaq: SELB June 2018 Safe Harbor / Disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. ("the company"), including without limitation, the progress of the Phase 1/2 clinical progra

May 9, 2018

Selecta Biosciences Announces First Quarter 2018 Financial Results and Provides Corporate Update 3-month Phase 2 data presented at PANLAR 2018 indicate SEL-212 (SVP-Rapamycin + pegsiticase) product profile may provide be

Selecta Biosciences Announces First Quarter 2018 Financial Results and Provides Corporate Update Watertown, Mass., May 9, 2018 - Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by

Apr 10, 2018

Selecta Biosciences Presents Positive New Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at PANLAR 2018 Congress 3-month Phase 2 data indicate SEL-212 (SVP-Rapamycin + pegsiticase) pr

Selecta Biosciences Presents Positive New Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at PANLAR 2018 Congress Watertown, Mass., April 10, 2018 - Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biopharmaceutical company focused o

Mar 15, 2018

Selecta Biosciences Announces Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update SEL-212 Severe Gout Program on Track; Additional Phase 2 Data for Higher Dose Cohorts to be Presented on Apri

Selecta Biosciences Announces Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update Watertown, Mass., March 15, 2018 - Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biol

Jan 8, 2018

jan2018investo Investor Presentation Nasdaq: SELB January 2018 Safe Harbor / Disclaimer 2 Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. ("the company"

Investor Presentation Nasdaq: SELB January 2018 Safe Harbor / Disclaimer 2 Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. ("the company"), including without limitation, the progress of the Phase 1/2 clinical pr

Nov 7, 2017

Selecta Biosciences Announces Third Quarter 2017 Financial Results and Provides Corporate Update Patient Data From Ongoing Phase 2 Trial to be Presented Today at the American College of Rheumatology (ACR) 2017 Annual Mee

Selecta Biosciences Announces Third Quarter 2017 Financial Results and Provides Corporate Update Watertown, Mass., November 7, 2017 - Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapi

Oct 26, 2017

Selecta Biosciences Announces Important Additions to Senior Leadership Team

Selecta Biosciences Announces Important Additions to Senior Leadership Team Watertown, Mass., October 26, 2017 - Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwante

Aug 11, 2017

Selecta Biosciences Announces Second Quarter 2017 Financial Results and Provides Corporate Update Positive Data from Ongoing Phase 2 Study of SEL-212 Reported at Clinical Meetings in June 2017 Further Preclinical Data Co

Selecta Biosciences Announces Second Quarter 2017 Financial Results and Provides Corporate Update Watertown, Mass., August 11, 2017 - Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapi

Jun 15, 2017

Selecta Biosciences Reports Data from Ongoing Phase 2 Trial of Lead Candidate, SEL-212, in Development for Chronic Severe Gout Watertown, Mass.

Selecta Biosciences Reports Data from Ongoing Phase 2 Trial of Lead Candidate, SEL-212, in Development for Chronic Severe Gout Watertown, Mass., June 15, 2017 - Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full po

May 11, 2017

Selecta Biosciences Announces First Quarter 2017 Financial Results and Provides Corporate Update On Track to Complete Phase 2 Trial of Lead Product Candidate, SEL-212, in 2017 Licensed LMB-100, a Clinical-Stage Candidate

Selecta Biosciences Announces First Quarter 2017 Financial Results and Provides Corporate Update Watertown, Mass., May 11, 2017 - Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies b

Mar 27, 2017

Selecta Biosciences Announces Fourth Quarter and Year End 2016 Financial Results and Provides Corporate Update New Data from Ongoing SEL-212 Phase 2 Trial Show Persistent Clinical Activity After Repeat Administration in

Selecta Biosciences Announces Fourth Quarter and Year End 2016 Financial Results and Provides Corporate Update Watertown, Mass., March 27, 2017 - Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biopharmaceutical company focused on developing biologic therapies for ra

Nov 10, 2016

Selecta Biosciences Announces Third Quarter 2016 Financial Results and Provides Corporate Update Phase 2 Trial of SEL-212 for Treatment of Gout Initiated SEL-212 Phase 1 Clinical Data to be Presented December 7-8, 2016 P

Selecta Biosciences Announces Third Quarter 2016 Financial Results and Provides Corporate Update Watertown, Mass., November 10, 2016 - Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biopharmaceutical company developing a novel class of targeted antigen-specific immu

Aug 9, 2016